Coagulopathy of liver disease

• Coagulopathy in patients with liver disease results from impairments in the clotting and fibrinolytic systems, as well as from reduced number and function of platelets.

• Parenteral vitamin K replacement corrects coagulopathy related to biliary obstruction, bacterial overgrowth, or malnutrition. Vitamin K is less effective for coagulopathy caused by severe parenchymal liver injury.

• Transfusion of fresh frozen plasma is the hallmark of treatment of significant coagulopathy in patients with liver disease and active bleeding.

• Transfusion of fresh frozen plasma also reverses moderate to severe coagulopathy of cirrhosis prior to invasive procedures.

• Cryoprecipitate is useful for severe coagulopathy with hypofibrinogenemia, especially when avoidance of volume overload is desired.

• Exchange plasmapheresis is useful in selected patients with coagulopathy due to liver disease, in whom fresh frozen plasma fails to correct coagulopathy or in patients who have coexistent severe fluid overload.

• Platelet transfusions, pooled or single donor, are useful in thrombocytopenic patients prior to performing invasive procedures or in the presence of significant bleeding, especially when the platelet count is below 50,000/mL.

• The use of recombinant factor VIIa and thrombopoietin therapy for correction of coagulopathy and thrombocytopenia, respectively, in patients with cirrhosis, is currently under investigation.

• Therapy with prothrombin complex concentrates, 1-deamino-8-D-arginine vasopressin and antithrombin III concentrates for the management of coagulopathy caused by liver disease can be hazardous and the use of these products is considered investigational at the present time.

1. Brophy MT, Fiore LD, Deykin D: Hemostasis. In Hepatology: A Textbook of Liver Disease, edn 3. Edited by Zakim D, Boyer TD. Philadelphia: WB Saunders; 1996.

   Google Scholar 

2. Violi F, Ferro D, Basili S, et al.: Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. Hepatology 1993, 17:78–83. This study explored the relationship between clotting activation and tissue plasminogen activator and its inhibitor in cirrhotic patients with different degrees of liver failure.

   Article  PubMed  CAS  Google Scholar 

3. Mammen EF: Coagulation defects in liver disease. Med Clin North Am 1994, 78(3):545–554. A fairly comprehensive review of the hemostasic alterations and their management in various liver diseases.

   PubMed  CAS  Google Scholar 

4. Sallah S, Bobzien W: Bleeding problems in patients with liver disease. Ways to manage the many hepatic effects on coagulation. Postgrad Med 1999, 106(4):187–195. A good, practical guide to the diagnosis and treatment of coagulopathy of liver disease.

   PubMed  CAS  Google Scholar 

5. Kelly DA, Tuddenham EG: Haemostatic problems in liver disease. Gut 1986, 3:339–349.

   Google Scholar 

6. Lind SE: The bleeding time does not predict surgical bleeding. Blood 1991, 77(12):2547–2552.

   PubMed  CAS  Google Scholar 

7. Furie B, Furie BC: Molecular basis of vitamin K-dependent gamma-carboxylation. Blood 1990, 75(9):1753–1762.

   PubMed  CAS  Google Scholar 

8. Ragni MV, Lewis JH, Spero JA: Ascites-induced LeVeen shunt coagulopathy. Ann Surg 1983, 198(1):91–95.

   Article  PubMed  CAS  Google Scholar 

9. Violi F, Basili S, Ferro D, et al.: Association between high values of D-dimer and tissue plasminogen activator activity and first gastrointestinal bleeding in cirrhotic patients. Thromb Hemost 1996, 76(2):177–183. Association between hyperfibrinolysis and gastrointestinal bleeding in cirrhotic patients is studied.

   Google Scholar 

10. Violi F, Ferro D, Basili S, et al.: Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology 1992, 4:672–676.

    Article  Google Scholar 

11. Cowan DH: Effect of alcoholism on hemostasis. Semin Hematol 1980, 2:137–147.

    Google Scholar 

12. Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, et al.: Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997, 6:1930–1937. This preliminary trial evaluates the efficacy of recombinant factor VIIa in the correction of coagulation parameters in a select group of nonbleeding cirrhotics.

    Article  Google Scholar 

13. Peck-Radosavljevic M, Wichlas M, Zacherl J, et al.: Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000, 3:795–801.

    Google Scholar 

Download references

Authors and Affiliations

1. Center for Liver Disease, Albert Einstein Medical Center, 5401 Old York Road, Klein Building, Suite 509, 19141, Philadelphia, PA, USA

   Vivek Kaul MD & Santiago J. Munoz MD

Cite this article

Kaul, V., Munoz, S.J. Coagulopathy of liver disease. Curr Treat Options Gastro 3, 433–437 (2000). https://doi.org/10.1007/s11938-000-0030-y

Download citation

• Issue Date: December 2000

• DOI: https://doi.org/10.1007/s11938-000-0030-y

Keywords